Is Pfizer Stock a Yield Trap?

When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.Patent-protected exclusivity is the reason pharmaceutical stocks are known for delivering reliably growing dividend payments. Unfortunately, some of Pfizer's (NYSE: PFE) most important patents are expiring soon.Shares of Pfizer have been beaten down about 60% from their previous peak in 2021. The price is way down, but the company has raised its dividend payout every year since 2009. At its beaten-down price, the stock offers an enormous 7.1% yield.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool